HERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma

British Journal of Cancer

Volumn 112, Issue 6, 2015, Pages 1076-1087

  Lastraioli, E ^a   Perrone, G ^b   Sette, A ^a   Fiore, A ^a   Crociani, O ^a   Manoli, S ^a   D'Amico, M ^a,c   Masselli, M ^a   Iorio, J ^a   Callea, M ^b   Borzomati, D ^b   Nappo, G ^b   Bartolozzi, F ^d   Santini, D ^b   Bencini, L ^e   Farsi, M ^e   Boni, L ^e   Di Costanzo, F ^f   Schwab, A ^g   Onetti Muda, A ^b   Coppola, R ^b   Arcangeli, A ^a   more..

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c DIVAL Toscana Srl   (Italy)

^d Casa di Cura Villa Letizia   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f Universitaria Careggi   (Italy)

^g UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

EGF R; hERG1 potassium channels; molecular imaging; pancreatic ductal adenocarcinoma (PDAC); prognosis

Indexed keywords

CRE RECOMBINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR PDX 1; ERG1 POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL GROWTH; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; FLUORESCENCE IMAGING; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIMARY CULTURE; PRIMARY TUMOR; PRIORITY JOURNAL; TISSUE MICROARRAY; TRANSGENIC MOUSE; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; CELL MOTION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84925340348     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.28     Document Type: Article

References (44)

1. Ansari D, Rosendahl A, Elebro J, Andersson R (2011) Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg 98: 1041-1055.
2. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, Ramm GA, Buchler M, Friess H, McCarroll JA, Keogh G, Merrett N, Pirola R, Wilson JS (2004) Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29: 179-187.
3. Arcangeli A (2005) Expression and role of hERG channels in cancer cells. Novartis Found Symp 266: 225-232, discussion 232-4.
4. Arcangeli A, Becchetti A (2006) Complex functional interaction between integrin receptors and ion channels. Trends Cell Biol 16: 631-639.
5. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A (2009) Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem 16: 66-93.
6. Becchetti A (2011) Ion channels and transporters in cancer. 1. Ion channels and cell proliferation in cancer. Am J Physiol Cell Physiol 301: C255-C265.
7. Bera A, Zhao S, Cao L, Chiao PJ, Freeman JW (2013) Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-kB axis that induces expression of MMP9 and uPA in human pancreas progenitor cells. PLoS One 8: e82282.
8. Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Klein S, Kojouharoff G, Barner M, Geissler M, Greten TF, Mansmann U, Kirchner T, Heinemann V (2013) EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer 108: 469-476.
9. Crociani O, Zanieri F, Pillozzi S, Lastraioli E, Stefanini M, Fiore A, Fortunato A, DAmico M, Masselli M, De Lorenzo E, Gasparoli L, Chiu M, Bussolati O, Becchetti A, Arcangeli A (2013) hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer. Sci Rep 3: 3308.
10. Crociani O, Lastraioli E, Boni L, Pillozzi S, Romoli MR, DAmico M, Stefanini M, Crescioli S, Taddei A, Bencini L, Bernini M, Farsi M, Beghelli S, Scarpa A, Messerini L, Tomezzoli A, Vindigni C, Morgagni P, Saragoni L, Giommoni E, Gasperoni S, Di Costanzo F, Roviello F, De Manzoni G, Bechi P, Arcangeli A (2014) hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications. Clin Cancer Res 20: 1502-1512.
11. Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39: 425-435.
12. Dozynkiewicz MA, Jamieson NB, Macpherson I, Grindlay J, van den Berghe PV, von Thun A, Morton JP, Gourley C, Timpson P, Nixon C, McKay CJ, Carter R, Strachan D, Anderson K, Sansom OJ, Caswell PT, Norman JC (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev Cell 22: 131-145.
13. Faravelli L, Arcangeli A, Olivotto M, Wanke E (1996) A HERG-like K+ channel in rat F-11 DRG cell line: pharmacological identification and biophysical characterization. J Physiol 496(Pt 1): 13-23.
14. Feng J, Yu J, Pan X, Li Z, Chen Z, Zhang W, Wang B, Yang L, Zhang G, Xu Z (2014) HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Oncotarget 5: 5832-5844.
15. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) IARC CancerBase No. 11. Available from http://globocan.iarc.fr accessed on 26 February 2014.
16. Fiore A, Carraresi L, Morabito A, Polvani S, Fortunato A, Lastraioli E, Femia AP, De Lorenzo E, Caderni G, Arcangeli A (2013) Characterization of hERG1 channel role in mouse colorectal carcinogenesis. Cancer Med 2: 583-594.
17. Gasparoli L, DAmico M, Masselli M, Pillozzi S, Caves R, Khuwaileh R, Tiedke W, Mugridge K, Pratesi A, Mitcheson JS, Basso G, Becchetti A, Arcangeli A (2015) The new pyrimido-indole compound CD-160130 preferentially inhibits the KV11.1B isoform and produces antileukemic effects without cardio-toxicity. Mol Pharmacol 87: 183-196.
18. Hartel M, di Mola FF, Selvaggi F, Mascetta G, Wente MN, Felix K, Giese NA, Hinz U, Di Sebastiano P, Büchler MW, Friess H (2006) Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut 55: 519-528.
19. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450.
20. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483.
21. Krasinskas AM (2011) EGFR signaling in colorectal carcinoma. Patholog Res Int 2011: 932932.
22. Lastraioli E, Taddei A, Messerini L, Comin CE, Festini M, Giannelli M, Tomezzoli A, Paglierani M, Mugnai G, De Manzoni G, Bechi P, Arcangeli A (2006) hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barretts esophagus. J Cell Physiol 209: 398-404.
23. Lastraioli E, Bencini L, Bianchini E, Romoli MR, Crociani O, Giommoni E, Messerini L, Gasperoni S, Moretti R, Di Costanzo F, Boni L, Arcangeli A (2012) hERG1 Channels and Glut-1 as independent prognostic indicators of worse outcome in stage I and II colorectal cancer: a pilot study. Transl Oncol 5: 105-112.
24. Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A (2005) Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer 115: 924-929.
25. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
26. Mulcahy HE, Lyautey J, Lederrey C, qi Chen X, Anker P, Alstead EM, Ballinger A, Farthing MJ, Stroun M (1998) A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 4: 271-275.
27. Neuzillet C, de Gramont A, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E (2014) Perspectives of TGF-b inhibition in pancreatic and hepatocellular carcinomas. Oncotarget 5: 78-94.
28. Olszewski U, Hlozek M, Hamilton G (2010) Activation of Na+/H+ exchanger 1 by neurotensin signaling in pancreatic cancer cell lines. Biochem Biophys Res Commun 393: 414-419.
29. Partensky C (2013) Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope? Pancreas 42: 729-739.
30. Pedersen SF, Stock C (2013) Ion channels and transporters in cancer: pathophysiology, regulation, and clinical potential. Cancer Res 73: 1658-1661.
31. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C (2005) COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology 46: 561-568.
32. Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, Boddi V, Pegoraro L, Becchetti A, Arcangeli A (2007) VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 110: 1238-1250.
33. Pillozzi S, Arcangeli A (2010) Physical and functional interaction between integrins and hERG1 channels in cancer cells. Adv Exp Med Biol 674: 55-67.
34. Prevarskaya N, Skryma R, Shuba Y (2010) Ion channels and the hallmarks of cancer. Trends Mol Med 16: 107-121.
35. Provost JJ, Wallert MA (2013) Inside out: targeting NHE1 as an intracellular and extracellular regulator of cancer progression. Chem Biol Drug Des 81: 85-101.
36. Rosati B, Marchetti P, Crociani O, Lecchi M, Lupi R, Arcangeli A, Olivotto M, Wanke E (2000) Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: the role of HERG K(+) channels in firing and release. FASEB J 14: 2601-2610.
37. Schönherr R, Rosati B, Hehl S, Rao VG, Arcangeli A, Olivotto M, Heinemann SH, Wanke E (1999) Functional role of the slow activation property of ERG K+ channels. Eur J Neurosci 11: 753-760.
38. Sette A, Spadavecchia J, Landoulsi J, Casale S, Haye B, Crociani O, Arcangeli A (2013) Development of novel anti-Kv 11.1 antibodyconjugated PEG-TiO2 nanoparticles for targeting pancreatic ductal adenocarcinoma cells. J Nanopart Res 15: 2111.
39. Siveke JT, Crawford HC (2012) KRAS above and beyond-EGFR in pancreatic cancer. Oncotarget 3: 1262-1263.
40. Sobin LH, Gospodarowicz M, Wittekind Ch (2009) TNM Classification of Malignant Tumors. UICC International Union Against Cancer, 7th ed. Wiley-Blackwell: New York.
41. Sontheimer H (2008) An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med 233: 779-791.
42. Soroceanu L, Manning Jr TJ, Sontheimer H (1999) Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers. J Neurosci 19: 5942-5954.
43. Taylor CR (1994) An exaltation of experts: concerted efforts in the standardization of immunohistochemistry. Hum Pathol 25: 2-11.
44. Zhou B, Irwanto A, Guo YM, Bei JX, Wu Q, Chen G, Zhang TP, Lei JJ, Feng QS, Chen LZ, Liu J, Zhao YP (2012) Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma. Cancer Biol Ther 13: 871-879.